Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News NuCana PLC NCNA

Healthcare Biotechnology
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:NCNA)

NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

GlobeNewswire March 19, 2026

NuCana Appoints Theresa Bruce as Chief Operating Officer

GlobeNewswire January 6, 2026

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

GlobeNewswire December 10, 2025

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 13, 2025

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

GlobeNewswire November 5, 2025

NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025

GlobeNewswire October 18, 2025

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy

GlobeNewswire October 14, 2025

NuCana Compliant with All Nasdaq Continued Listing Criteria

GlobeNewswire September 5, 2025

NuCana to Present Data on NUC-7738's Synergy with PD-1 Inhibitors at the ESMO Congress 2025

GlobeNewswire September 3, 2025
View More News ››

Opinion & Analysis (NDAQ:NCNA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:NCNA)

NCNA... Might be a s good a time as any to start a position?

It's trading near the All-time low & post RS ; ) Last at $2.935 Will add on weakness ..... Happy Fryday !
Iseneschal - September 5, 2025

NCNA....Pre RS Pump today...LoL

Go ahead
Iseneschal - July 25, 2025

been wild volumes

follow the volume or follow the assets for the big scores
webminingdude - June 12, 2025

NCNA Upgrade out with 150$ Price Target Low Float 4$

NCNA Upgrade out with 150$ price target Currently 4$ Low Float Phase 2 Data due soon https://www.investing.com/news/company-news/nucana...
10QKing - August 19, 2024

NCNA.....day 2 of volume and Price Action

On watch....no News Release No positon
Iseneschal - March 13, 2024
View more Bullboard ››

NurExone Biologic

NurExone Biologic

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based ...
View More »

Podcasts